Cannell & Spears’s Idexx Laboratories IDXX Stock Holding History

Cannell & Spears’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.03M	Sell	7,176 -1,900	-21%	-$1.22M	0.08%	147
2025 Q4	$6.14M	Hold	9,076	–	–	0.11%	122
2025 Q3	$5.8M	Buy	9,076 +5	+0.1%	+$3.04K	0.11%	131
2025 Q2	$4.87M	Sell	9,071 -1	-0%	-$478	0.1%	140
2025 Q1	$3.81M	Buy	9,072 +7,901	+675%	+$3.43M	0.08%	154
2024 Q4	$484K	Sell	1,171 -399	-25%	-$175K	0.01%	288
2024 Q3	$793K	Buy	1,570 +400	+34%	+$194K	0.02%	258
2024 Q2	$570K	Sell	1,170 -400	-25%	-$201K	0.01%	260
2024 Q1	$848K	Buy	1,570 +400	+34%	+$219K	0.02%	238
2023 Q4	$649K	Hold	1,170	–	–	0.05%	122
2023 Q3	$512K	Hold	1,170	–	–	0.04%	131
2023 Q2	$588K	Buy	1,170 +400	+52%	+$192K	0.05%	126
2023 Q1	$385K	Hold	770	–	–	0.03%	159
2022 Q4	$314K	Buy	+770	New	+$299K	0.03%	175

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cannell & Spears's IDXX Position: Q1 2026 in Review

Cannell & Spears reduced its Idexx Laboratories (IDXX) stake by 21% in Q1 2026, selling an estimated $1.22M and leaving 7,176 shares worth $4.03M. The position accounts for 0.08% of the portfolio, ranked #147.

Cannell & Spears first reported a position in IDXX in Q4 2022 and has held it in 14 quarters since. The position peaked at $6.14M in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Cannell & Spears held 7,176 shares of Idexx Laboratories worth $4.03M as of Q1 2026.
Cannell & Spears sold 1,900 Idexx Laboratories shares in Q1 2026, an estimated $1.22M.
Idexx Laboratories made up 0.08% of Cannell & Spears's portfolio in Q1 2026, its #147 holding.
Cannell & Spears first reported a position in Idexx Laboratories in Q4 2022 and has held it in 14 quarters since.
Cannell & Spears's Idexx Laboratories position peaked at $6.14M in Q4 2025.
1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.